子宫颈透明细胞癌合并双侧卵巢透明细胞癌1例
A Case of Cervical Clear Cell Carcinoma Concurrent with Bilateral Ovarian Clear Cell Carcinoma
DOI: 10.12677/acm.2025.1541231, PDF,   
作者: 张雅璇*#, 孙安邈*, 张 扬:山东大学妇儿与生殖健康研究院,生殖医学与子代健康全国重点实验室,山东 济南;章玲玲:山东大学齐鲁医院妇产科,山东 济南
关键词: 子宫颈透明细胞癌己烯雌酚病例报告Clear Cell Carcinoma of the Cervix Diethylstilbestrol Case Report
摘要: 目的:探讨子宫颈透明细胞癌(Clear cell cervical adenocarcinoma, CCAC)的临床特征,提高临床医师对该病的认识。特别是对于年轻患者,应警惕其高度侵袭性,重视早期诊断和综合治疗,以改善患者预后。方法:本文报道山东大学齐鲁医院收治的1例21岁特发性子宫颈透明细胞癌合并双侧卵巢透明细胞癌患者,分析其临床表现、影像学及病理学特征、诊断及治疗经过,并结合既往文献进行回顾与总结。结论:CCAC是一种罕见且高度侵袭性的子宫颈腺癌,在年轻女性中较少见,且与人乳头瘤病毒(HPV)感染无明显相关性。临床上对于不明原因的异常阴道流血、子宫颈肿物或盆腔包块的年轻患者,应提高警惕,尽早行影像学及病理学检查,以实现早发现、早诊断、早治疗。此外,未来仍需进一步探索CCAC的分子机制及最佳治疗策略,以优化个体化治疗方案,提高患者长期生存率。
Abstract: Objective: To investigate the clinical characteristics of clear cell carcinoma of the cervix and enhance clinicians’ awareness of this disease. Particular attention should be given to its highly aggressive nature in young patients, emphasizing the importance of early diagnosis and comprehensive treatment to improve prognosis. Methods: This study reports a case of a 21-year-old patient diagnosed with idiopathic CCAC concurrent with bilateral ovarian clear cell carcinoma, treated at Qilu Hospital of Shandong University. The patient’s clinical presentation, imaging and pathological characteristics, diagnostic process, and treatment course were analyzed. A review of relevant literature was also conducted for further discussion. Conclusion: CCAC is a rare and highly aggressive subtype of cervical adenocarcinoma, with low prevalence in young women and no significant correlation with human papillomavirus infection. Clinicians should remain vigilant when encountering young patients presenting with unexplained abnormal uterine bleeding, cervical masses, or pelvic tumors, and should promptly conduct imaging and pathological evaluations to facilitate early detection, accurate diagnosis, and timely intervention. Furthermore, future research should focus on elucidating the molecular mechanisms underlying CCAC and optimizing therapeutic strategies to improve individualized treatment plans and enhance long-term survival outcomes.
文章引用:张雅璇, 孙安邈, 章玲玲, 张扬. 子宫颈透明细胞癌合并双侧卵巢透明细胞癌1例[J]. 临床医学进展, 2025, 15(4): 2707-2714. https://doi.org/10.12677/acm.2025.1541231

参考文献

[1] Small, W., Bacon, M.A., Bajaj, A., Chuang, L.T., Fisher, B.J., Harkenrider, M.M., et al. (2017) Cervical Cancer: A Global Health Crisis. Cancer, 123, 2404-2412. [Google Scholar] [CrossRef] [PubMed]
[2] Reich, O., Tamussino, K., Lahousen, M., Pickel, H., Haas, J. and Winter, R. (2000) Clear Cell Carcinoma of the Uterine Cervix: Pathology and Prognosis in Surgically Treated Stage IB-IIB Disease in Women Not Exposed in Utero to Diethylstilbestrol. Gynecologic Oncology, 76, 331-335. [Google Scholar] [CrossRef] [PubMed]
[3] Pal, S., Jana, S. and Bose, K. (2015) Clear Cell Carcinoma of Cervix in a Postmenopausal Woman: A Case Report. Journal of Mid-Life Health, 6, 85-87. [Google Scholar] [CrossRef] [PubMed]
[4] Herbst, A.L., Ulfelder, H. and Poskanzer, D.C. (1999) Adenocarcinoma of the Vagina. Association of Maternal Stilbestrol Therapy with Tumor Appearance in Young Women. American Journal of Obstetrics and Gynecology, 181, 1574-1575. [Google Scholar] [CrossRef] [PubMed]
[5] Huo, D., Anderson, D. and Herbst, A.L. (2018) Follow-Up of Patients with Clear-Cell Adenocarcinoma of the Vagina and Cervix. New England Journal of Medicine, 378, 1746-1748. [Google Scholar] [CrossRef] [PubMed]
[6] Stolnicu, S., Karpathiou, G., Guerra, E., Mateoiu, C., Reques, A., Garcia, A., et al. (2022) Clear Cell Carcinoma (CCC) of the Cervix Is a Human Papillomavirus (HPV)-Independent Tumor Associated with Poor Outcome. American Journal of Surgical Pathology, 46, 765-773. [Google Scholar] [CrossRef] [PubMed]
[7] Stolnicu, S., Talia, K.L. and McCluggage, W.G. (2020) The Evolving Spectrum of Precursor Lesions of Cervical Adenocarcinomas. Advances in Anatomic Pathology, 27, 278-293. [Google Scholar] [CrossRef] [PubMed]
[8] Nakamura, K., Nakayama, K., Minamoto, T., Ishibashi, T., Ohnishi, K., Yamashita, H., et al. (2018) Lynch Syndrome-Related Clear Cell Carcinoma of the Cervix: A Case Report. International Journal of Molecular Sciences, 19, Article 979. [Google Scholar] [CrossRef] [PubMed]
[9] Ueno, S., Sudo, T., Oka, N., Wakahashi, S., Yamaguchi, S., Fujiwara, K., et al. (2013) Absence of Human Papillomavirus Infection and Activation of PI3K-AKT Pathway in Cervical Clear Cell Carcinoma. International Journal of Gynecological Cancer, 23, 1084-1091. [Google Scholar] [CrossRef] [PubMed]
[10] Kim, S.H., Basili, T., Dopeso, H., Da Cruz Paula, A., Bi, R., Issa Bhaloo, S., et al. (2022) Recurrent WWTR1S89W Mutations and Hippo Pathway Deregulation in Clear Cell Carcinomas of the Cervix. The Journal of Pathology, 257, 635-649. [Google Scholar] [CrossRef] [PubMed]
[11] Hasegawa, K., Nagao, S., Yasuda, M., Millan, D., Viswanathan, A.N., Glasspool, R.M., et al. (2014) Gynecologic Cancer Intergroup (GCIG) Consensus Review for Clear Cell Carcinoma of the Uterine Corpus and Cervix. International Journal of Gynecological Cancer, 24, S90-S95. [Google Scholar] [CrossRef] [PubMed]
[12] Hiromura, T., Tanaka, Y.O., Nishioka, T., Satoh, M. And Tomita, K. (2009) Clear Cell Adenocarcinoma of the Uterine Cervix Arising from a Background of Cervical Endometriosis. The British Journal of Radiology, 82, e20-e22. [Google Scholar] [CrossRef] [PubMed]
[13] 王遥, 杨佳欣. 非HPV感染相关宫颈腺癌的研究进展[J]. 国际妇产科学杂志, 2018, 45(1): 60-65.
[14] Green, J.A., Kirwan, J.J., Tierney, J., Vale, C.L., Symonds, P.R., Fresco, L.L., et al. (2005) Concomitant Chemotherapy and Radiation Therapy for Cancer of the Uterine Cervix. Cochrane Database of Systematic Reviews, 2015, CD002225. [Google Scholar] [CrossRef] [PubMed]
[15] Lim, M.C., Lee, M., Shim, S.H., Nam, E.J., Lee, J.Y., Kim, H.J., et al. (2017) Practice Guidelines for Management of Cervical Cancer in Korea: A Korean Society of Gynecologic Oncology Consensus Statement. Journal of Gynecologic Oncology, 28, e22. [Google Scholar] [CrossRef] [PubMed]
[16] Lachiewicz, M.P., Khanna, N., Gordon, A.N. and Horowitz, I.R. (2017) Long-Term Remission of Clear Cell Carcinoma of the Cervix after Chemoradiation with 109 Cycles of Paclitaxel: A Case Report and Literature Review. European Journal of Gynaecological Oncology, 38, 456-458.
[17] Jenkins, D., Molijn, A., Kazem, S., Pirog, E.C., Alemany, L., de Sanjosé, S., et al. (2020) Molecular and Pathological Basis of HPV-Negative Cervical Adenocarcinoma Seen in a Global Study. International Journal of Cancer, 147, 2526-2536. [Google Scholar] [CrossRef] [PubMed]
[18] Tewari, K.S., Sill, M.W., Long, H.J., Penson, R.T., Huang, H., Ramondetta, L.M., et al. (2014) Improved Survival with Bevacizumab in Advanced Cervical Cancer. New England Journal of Medicine, 370, 734-743. [Google Scholar] [CrossRef] [PubMed]
[19] Naumann, R.W., Hollebecque, A., Meyer, T., Devlin, M.J., Oaknin, A., et al. (2019) Safety and Efficacy of Nivolumab Monotherapy in Recurrent or Metastatic Cervical, Vaginal, or Vulvar Carcinoma: Results from the Phase I/II Check Mate 358 Trial. Journal of Clinical Oncology, 37, 2825-2834.
[20] Meric-Bernstam, F., Makker, V., Oaknin, A., Oh, D., Banerjee, S., González-Martín, A., et al. (2024) Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Expressing Solid Tumors: Primary Results from the Destiny-Pantumor02 Phase II Trial. Journal of Clinical Oncology, 42, 47-58. [Google Scholar] [CrossRef] [PubMed]
[21] Wang, Y., Gong, J., Wang, A., Wei, J., Peng, Z., Wang, X., et al. (2024) Disitamab Vedotin (RC48) Plus Toripalimab for HER2-Expressing Advanced Gastric or Gastroesophageal Junction and Other Solid Tumours: A Multicentre, Open Label, Dose Escalation and Expansion Phase 1 Trial. E Clinical Medicine, 68, Article 102415. [Google Scholar] [CrossRef] [PubMed]
[22] 中国抗癌协会宫颈癌专业委员会, 朱滔, 林仲秋. 子宫颈透明细胞癌诊治指南(2024年版) [J]. 中国实用妇科与产科杂志, 2024, 40(8): 810-818.
[23] Abu-Rustum, N.R., Yashar, C.M., Bean, S., Bradley, K., Campos, S.M., Chon, H.S., et al. (2020) NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal of the National Comprehensive Cancer Network, 18, 660-666. [Google Scholar] [CrossRef] [PubMed]
[24] Stolnicu, S., Barsan, I., Hoang, L., Patel, P., Terinte, C., Pesci, A., et al. (2018) International Endocervical Adenocarcinoma Criteria and Classification (IECC). American Journal of Surgical Pathology, 42, 214-226. [Google Scholar] [CrossRef] [PubMed]
[25] Camp, E.A., Prehn, A.W., Shen, J., Herbst, A.L., Strohsnitter, W.C., Hobday, C.D., et al. (2015) Factors Associated with a Lack of Pap Smear Utilization in Women Exposed in Utero to Diethylstilbestrol. Journal of Women’s Health, 24, 308-315. [Google Scholar] [CrossRef] [PubMed]
[26] Troisi, R., Hatch, E.E., Palmer, J.R., Titus, L., Robboy, S.J., Strohsnitter, W.C., et al. (2016) Prenatal Diethylstilbestrol Exposure and High-Grade Squamous Cell Neoplasia of the Lower Genital Tract. American Journal of Obstetrics and Gynecology, 215, 322.e1-322.e8. [Google Scholar] [CrossRef] [PubMed]